Gilead Sciences

AbbVie's Rinvoq label portends safety warnings for future JAKs—including Gilead's
AbbVie's Rinvoq label portends safety warnings for future JAKs—including Gilead's
Fierce Pharma
JAK inhibitors
AbbVie
Rinvoq
FDA
Gilead Sciences
Flag link:
FDA AdCom backs Gilead's move to expand Descovy label — but stops short of endorsing broad PrEP use
FDA AdCom backs Gilead's move to expand Descovy label — but stops short of endorsing broad PrEP use
Endpoints
FDA
Gilead Sciences
HIV
Descovy
PrEP
Flag link:
Regulators, Gilead at odds over HIV drug's use in women
Regulators, Gilead at odds over HIV drug's use in women
Biopharma Dive
Gilead Sciences
HIV
Descovy
Flag link:
Gilead looks to Galapagos deal to double research capacity
Gilead looks to Galapagos deal to double research capacity
Fierce Biotech
Gilead Sciences
Daniel O'Day
Galapagos
R&D
Flag link:
Gilead Sciences Reports Improving Revenue in the 2nd Quarter
Gilead Sciences Reports Improving Revenue in the 2nd Quarter
Motley Fool
Gilead Sciences
earnings
Biktarvy
Flag link:
Gilead's exec search won't hurt its deal search: CEO
Gilead's exec search won't hurt its deal search: CEO
Fierce Pharma
Gilead Sciences
M&A
Daniel O'Day
Flag link:
Busy Gilead crew throws struggling biotech a lifeline, with some cash upfront and hundreds of millions in biobucks for HIV deal
Busy Gilead crew throws struggling biotech a lifeline, with some cash upfront and hundreds of millions in biobucks for HIV deal
Endpoints
Gilead Sciences
Durect
HIV
hepatitis B
extended release
Flag link:
Novartis licenses out early antiviral work to Gilead
Novartis licenses out early antiviral work to Gilead
Fierce Biotech
Gilead Sciences
Novartis
antivirals
Flag link:
These 5 Firms Could Buy Celgene's Otezla Ahead Of The Bristol Merger
These 5 Firms Could Buy Celgene's Otezla Ahead Of The Bristol Merger
Investors Business Daily
Bristol-Myers Squibb
Celgene
M&A
Otezla
Gilead Sciences
Amgen
Regeneron
Eli Lilly
JNJ
Flag link:
Gilead's Kite builds cell therapy manufacturing quickly even as Yescarta sales grow slowly
Gilead's Kite builds cell therapy manufacturing quickly even as Yescarta sales grow slowly
Fierce Pharma
Gilead Sciences
Kte Pharma
Yescarta
CAR-T
cell therapy
Flag link:
Gilead and Novartis Seek to Expand What FDA Considers as Real-World Data and Real-World Evidence
Gilead and Novartis Seek to Expand What FDA Considers as Real-World Data and Real-World Evidence
RAPS.org
FDA
Gilead Sciences
Novartis
RWE
real world data
real world evidence
Flag link:
Looking to resolve lingering doubts, Gilead unleashes a $5B late-stage cash alliance with Galapagos
Looking to resolve lingering doubts, Gilead unleashes a $5B late-stage cash alliance with Galapagos
Endpoints
Gilead Sciences
Galapagos
IPF
osteoarthritis
Flag link:
Christi Shaw, inspired by her sister’s cancer, named CEO of Kite Pharma, Gilead’s anti-cancer unit
Christi Shaw, inspired by her sister’s cancer, named CEO of Kite Pharma, Gilead’s anti-cancer unit
Stat
Christi Shaw
Kite Pharma
Gilead Sciences
cancer
Pharma CEOs
Flag link:
Faced with a PhIII flop in NASH, Gilead is sequencing 15,000 patients to find new drugs
Faced with a PhIII flop in NASH, Gilead is sequencing 15,000 patients to find new drugs
Endpoints
Gilead Sciences
NASH
Renown Institute
gene sequencing
Flag link:
Pfizer's Xeljanz drops off top June TV spenders list—and Gilead's Biktarvy fills the void
Pfizer's Xeljanz drops off top June TV spenders list—and Gilead's Biktarvy fills the void
Fierce Pharma
AbbVie
Humira
Gilead Sciences
Biktarvy
Truvada
Pfizer
Xeljanz
television ads
DTC ads
Flag link:
Two Experimental Drugs Show Promise in Inhibiting Ebola Virus
Two Experimental Drugs Show Promise in Inhibiting Ebola Virus
BioSpace
CDC
ebola virus
Gilead Sciences
remdesivir
Mapp Biopharmaceutical
ZMapp
Flag link:
Gilead and Lyndra Team Up to Develop Long-Acting HIV Therapies
Gilead and Lyndra Team Up to Develop Long-Acting HIV Therapies
BioSpace
Gilead Sciences
Lyndra Therapeutics
HIV
Flag link:
FDA Eliminates REMS for HIV Drug Truvada and its Generics
FDA Eliminates REMS for HIV Drug Truvada and its Generics
RAPS.org
FDA
Gilead Sciences
Truvada
HIV
REMS
Flag link:
Watch out AbbVie: Gilead is fast on your heels at the FDA with rival JAK inhibitor filgotinib
Watch out AbbVie: Gilead is fast on your heels at the FDA with rival JAK inhibitor filgotinib
Endpoints
Gilead Sciences
AbbVie
FDA
JAK inhibitors
filgotinib
Upadacitinib
rheumatoid arthritis
Flag link:
The Week Ahead In Biotech: Pending Clinical Readouts In Focus
The Week Ahead In Biotech: Pending Clinical Readouts In Focus
Yahoo/Benzinga
Retrophin
Karyopharm
Celyad
uniQure
Sangamo Therapeutics
Catalyst Biosciences
Novo Nordisk
Reata Pharmaceuticals
Vertex Pharmaceuticals
Bellicum
Gilead Sciences
Jaguar Health
TRACON Pharmaceuticals
FibroGen
Aslan Pharma
ObsEva
Sorrento Therapeutics
Flag link:

Pages